> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Travere's Filspari Sales Climb 120% To $200.2 Million, Yet A $113.1 Million Licensing Charge Drives A Loss
- URL: https://www.bullished.co/traveres-filspari-sales-climb-120-to-200-2-million-yet-a-113-1-million-licensing-charge-6312ff69/
- Published: 2026-11-02T22:14:03.000Z
- Updated: 2026-11-02T22:14:03.000Z
- Description: The kidney-drug maker posted a $52.3 million third-quarter net loss against a $25.7 million profit a year earlier.
- Author: Matteo Parrino
- Tags: Earnings, TVTX, Industry: Healthcare

Travere Therapeutics, which develops therapies for rare kidney and metabolic diseases, said U.S. sales of its drug Filspari reached [$200.2 million](https://www.sec.gov/Archives/edgar/data/0001438533/000143853326000074/a2026q3%5F8-kxex991.htm?ref=bullished.co) in the third quarter, up 120% from a year earlier. A $113.1 million charge for licensing a new drug candidate still pushed the company to a net loss, according to an [8-K filed Monday](https://www.sec.gov/Archives/edgar/data/0001438533/000143853326000074/tvtx-20261102.htm?ref=bullished.co).

## Growth against a licensing charge

Total U.S. net product sales were [$220.2 million](https://www.businesswire.com/news/home/20261102327521/en/Travere-Therapeutics-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co), against $113.2 million a year earlier. Filspari, approved for the kidney disease IgA nephropathy and, more recently, for FSGS, another rare kidney disease, supplied most of that. Sales of the company's tiopronin products slipped to $20.0 million from $22.3 million.

Net loss was $52.3 million, or $0.55 per share, versus net income of $25.7 million, or $0.29 per share, a year ago. The company booked a $113.1 million in-process research and development expense when its licensing deal with Everest Medicines for civorebrutinib closed.

On an adjusted basis, which excludes items such as stock-based pay, the net loss was $29.6 million, or $0.31 per share, against adjusted net income of $52.8 million a year earlier. For the first nine months, net loss was $124.2 million, compared with $28.3 million a year earlier.

## Demand and rising costs

Travere received [1,932 new patient](https://www.businesswire.com/news/home/20261102327521/en/Travere-Therapeutics-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) start forms in the quarter across IgAN and FSGS. CEO Eric Dube said the company remains early in reaching more than 100,000 addressable patients across the two conditions.

Research and development spending rose to $70.3 million from $51.9 million, which the company attributed mainly to the Phase 3 HARMONY study and manufacturing of pegtibatinase for classical homocystinuria. Selling, general and administrative expenses rose to $98.4 million from $71.0 million, which it tied to commercial investment in the FSGS launch and ongoing IgAN efforts.

Cash, cash equivalents and marketable securities stood at $471.8 million on September 30\. Convertible debt on the balance sheet was $603.5 million, up from $311.7 million at the end of 2025, while stockholders' equity was $22.6 million.

## Pipeline and a new CEO

Pegtibatinase, in the late-stage HARMONY study for classical homocystinuria, has topline results anticipated in the second half of 2027\. Travere plans to submit a U.S. investigational new drug application for civorebrutinib by year-end.

In September the company announced that Bradley Campbell will succeed Dube as CEO effective December 1, 2026\. Dube will stay on as an executive advisor through February 15, 2027.

Campbell takes over on December 1, and the civorebrutinib application is due by year-end.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Travere Therapeutics, Inc. (TVTX)](https://www.sec.gov/Archives/edgar/data/0001438533/000143853326000074/tvtx-20261102.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a2026q3\_8-kxex991.htm — Travere Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001438533/000143853326000074/a2026q3%5F8-kxex991.htm?ref=bullished.co) — SEC EDGAR
- [Travere Therapeutics Reports Third Quarter 2026 Financial Results](https://www.businesswire.com/news/home/20261102327521/en/Travere-Therapeutics-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) — businesswire.com